PDCD1 and cancer: Many bsAbs were developed to simultaneously target multiple immune checkpoints including programmed cell death 1 (PD-1), programmed death-ligand 1 (PD-L1) and Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) in order to enhance and re-direct a host’s immune response against cancer cells [24,60].